Pediatric Nephrology and Rheumatology Practice Patterns in Granulomatosis with Polyangiitis: A Midwest Pediatric Nephrology Consortium Study
Table 2
Characteristics of combination answer selections for Scenarios A-C.
N
Overall % if no specialty difference
Rheum %
Neph %
p-value of specialty difference
Scenario A
122
Cyclophosphamide
77
36.4
63.6
p=0.0114
+ IV/PO Steroid
71
92.2
+ Rituximab
26
61.5
38.5
p=0.001
+ Plasmapheresis
14
19.5
+ Rituximab + Plasmapheresis
9
11.7
Rituximab without Cyclophosphamide
39
60
+ IV/PO Steroid
36
92.3
+ IV/PO Steroid + Plasmapheresis
6
15.4
IV/PO Steroid without Cyclophosphamide, Rituximab, or Plasmapheresis
6
0
100
p<0.0001
Scenario B My preferences would be different than that chosen in Scenario A
75
61.5
Cyclophosphamide
61
81.3
+ IV/PO Steroid
52
85.3
+ Rituximab
23
65.2
34.8
p=0.0185
+ Plasmapheresis
40
65.6
+ Rituximab + Plasmapheresis
17
27.8
Rituximab without Cyclophosphamide
7
9.3
+ IV/PO Steroid
0
0
+ IV/PO Steroid + Plasmapheresis
7
100
Plasmapheresis without Cyclophosphamide or Rituximab
6
0
100
p<0.0001
Other
1
1.3
Scenario C My preferences would be different than that chosen in Scenario A
72
47.2
67.7
p=0.0232
Cyclophosphamide
45
63.4
+ IV/PO Steroid
40
88.9
+ Rituximab
16
35.6
+ Plasmapheresis
40
88.9
+ Rituximab + Plasmapheresis
13
32.5
Rituximab without Cyclophosphamide
13
18.3
+ IV/PO Steroid
12
92.3
+ IV/PO Steroid + Plasmapheresis
10
83.3
Plasmapheresis without Cyclophosphamide or Rituximab
11
13.4
Other
3
4.1
One subject chose ‘other’ but did not describe treatment in free text. One subject chose ‘other’ but did not describe treatment in free text; two did not select any option.
